First Quadrant’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-4,884
| Closed | -$1.42M | – | 535 |
|
|
2021
Q1 | $1.42M | Hold |
4,884
| – | – | 0.15% | 135 |
|
|
2020
Q4 | $1.22M | Hold |
4,884
| – | – | 0.12% | 144 |
|
|
2020
Q3 | $1.11M | Hold |
4,884
| – | – | 0.14% | 134 |
|
|
2020
Q2 | $852K | Hold |
4,884
| – | – | 0.11% | 185 |
|
|
2020
Q1 | $616K | Sell |
4,884
-927
| -16% | -$139K | 0.09% | 229 |
|
|
2019
Q4 | $888K | Hold |
5,811
| – | – | 0.07% | 240 |
|
|
2019
Q3 | $769K | Sell |
5,811
-110
| -2% | -$14.7K | 0.07% | 259 |
|
|
2019
Q2 | $840K | Sell |
5,921
-6
| -0.1% | -$814 | 0.06% | 329 |
|
|
2019
Q1 | $861K | Sell |
5,927
-11
| -0.2% | -$1.45K | 0.07% | 282 |
|
|
2018
Q4 | $672K | Sell |
5,938
-12
| -0.2% | -$1.5K | 0.05% | 303 |
|
|
2018
Q3 | $801K | Hold |
5,950
| – | – | 0.02% | 416 |
|
|
2018
Q2 | $668K | Sell |
5,950
-60
| -1% | -$6.49K | 0.01% | 451 |
|
|
2018
Q1 | $642K | Hold |
6,010
| – | – | 0.01% | 455 |
|
|
2017
Q4 | $658K | Hold |
6,010
| – | – | 0.01% | 500 |
|
|
2017
Q3 | $649K | Hold |
6,010
| – | – | 0.01% | 507 |
|
|
2017
Q2 | $608K | Hold |
6,010
| – | – | 0.01% | 509 |
|
|
2017
Q1 | $541K | Sell |
6,010
-45,020
| -88% | -$3.82M | 0.01% | 528 |
|
|
2016
Q4 | $3.89M | Sell |
51,030
-137,113
| -73% | -$10.4M | 0.08% | 266 |
|
|
2016
Q3 | $15.7M | Hold |
188,143
| – | – | 0.33% | 97 |
|
|
2016
Q2 | $15.5M | Buy |
188,143
+60
| +0% | +$4.94K | 0.34% | 99 |
|
|
2016
Q1 | $14.3M | Sell |
188,083
-73,893
| -28% | -$5.47M | 0.31% | 111 |
|
|
2015
Q4 | $21.1M | Buy |
261,976
+158,076
| +152% | +$11.4M | 0.46% | 71 |
|
|
2015
Q3 | $6.6M | Buy |
103,900
+79,500
| +326% | +$5.71M | 0.15% | 177 |
|
|
2015
Q2 | $1.72M | Sell |
24,400
-58,100
| -70% | -$4.3M | 0.04% | 300 |
|
|
2015
Q1 | $6.54M | Buy |
82,500
+41,500
| +101% | +$3.06M | 0.14% | 176 |
|
|
2014
Q4 | $2.61M | Hold |
41,000
| – | – | 0.06% | 255 |
|
|
2014
Q3 | $2.45M | Sell |
41,000
-41,500
| -50% | -$2.37M | 0.05% | 269 |
|
|
2014
Q2 | $4.42M | Sell |
82,500
-73,900
| -47% | -$4.06M | 0.1% | 213 |
|
|
2014
Q1 | $9.44M | Sell |
156,400
-33,100
| -17% | -$1.93M | 0.21% | 140 |
|
|
2013
Q4 | $10.1M | Hold |
189,500
| – | – | 0.23% | 124 |
|
|
2013
Q3 | $8.77M | Hold |
189,500
| – | – | 0.22% | 138 |
|
|
2013
Q2 | $7.78M | Buy |
+189,500
| New | +$8.12M | 0.21% | 146 |
|
Other funds holding CRL
First Quadrant's CRL Position: Q2 2021 in Review
First Quadrant sold out of Charles River Laboratories (CRL) in Q2 2021, closing a stake of 4,884 shares — an estimated $1.42M sold.
First Quadrant first reported a position in CRL in Q2 2013 and held it in 32 quarters. The position peaked at $21.1M in Q4 2015. 639 funds tracked by Wall St. Rank hold CRL as of Q2 2021.
- First Quadrant reported no remaining Charles River Laboratories position as of Q2 2021 after selling out during the quarter.
- First Quadrant sold 4,884 Charles River Laboratories shares in Q2 2021, an estimated $1.42M.
- First Quadrant first reported a position in Charles River Laboratories in Q2 2013 and held it in 32 quarters.
- First Quadrant's Charles River Laboratories position peaked at $21.1M in Q4 2015.
- 639 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2021.
Based on First Quadrant's 13F filing for Q2 2021, filed 23 Jul 2021.